Josef Khalil, MD
Family Medicine · Phoenix, AZNPI 1356403695
Payments from drug & device makers
Across 213 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$751
- Boehringer Ingelheim$581
- GSK$568
- Novo Nordisk$343
- Lilly USA, LLC$219
- Abbott$181
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,995100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $751 |
| Boehringer Ingelheim | 26 | $581 |
| GSK | 42 | $568 |
| Novo Nordisk | 21 | $343 |
| Lilly USA, LLC | 13 | $219 |
| Abbott | 8 | $181 |
| Bayer | 8 | $166 |
| Sumitomo Pharma America, Inc. | 6 | $131 |
| Lucid Diagnostics Inc. | 2 | $105 |
| Optinose US, Inc. | 5 | $102 |
| Amarin Pharma, Inc. | 6 | $86 |
| Merck | 5 | $85 |
| Exact Sciences | 5 | $81 |
| Astellas Pharma US Inc | 3 | $65 |
| AbbVie(2 entities) | 3 | $62 |
| Cleerly, Inc. | 1 | $59 |
| Boston Scientific | 3 | $58 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Medtronic | 2 | $37 |
| Amgen(2 entities) | 2 | $36 |
| Pfizer | 2 | $31 |
| Novartis | 2 | $29 |
| Edwards Lifesciences | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Linus Health, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,001 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 91 | $149,772 |
| OzempicSemaglutide | 89 | $115,672 |
| FarxigaDapagliflozin Propanediol | 81 | $94,170 |
| GemtesaVibegron | 81 | $82,509 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $71,823 |
| JanuviaSitagliptin Phosphate | 50 | $70,795 |
| TrulicityDulaglutide | 46 | $61,587 |
| MounjaroTirzepatide | 59 | $61,141 |
| TradjentaLinagliptin | 18 | $26,916 |
| ProliaDenosumab | 13 | $21,935 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $20,089 |
| VascepaIcosapent Ethyl | 16 | $15,634 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $13,794 |
| Fluticasone Propionate | 295 | $7,928 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $7,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $581 | $176,688109 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $219 | $122,728105 claims |
| Novo NordiskOzempic | $343 | $115,67289 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $751 | $114,25999 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $131 | $82,50981 claims |
| GSKTrelegy Ellipta | $568 | $71,82350 claims |
| MerckJanuvia | $85 | $70,79550 claims |
| AmgenProlia | $36 | $21,93513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Phoenix
- Brock MerrittPhoenix$8.4M
- Douglas CunninghamPhoenix$4.9M
- Jeffrey ZacherPhoenix$2M
- Trisha TavaresPhoenix$1.6M
- David FrancykPhoenix$1.3M
- James BeachPhoenix$1.2M
- Peter LevinsPhoenix$971K
- Elysa ShawPhoenix$774K
- Mitchell EdelsteinPhoenix$741K
- Brian DedinskyPhoenix$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.